 |
19 Diseases |  |
0 Trials |
|
0 Trials |  |
67 News |  |
| «12 |
- | lorukafusp alfa (APN301) / Apeiron Biologics
Trial completion, Trial initiation date: Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors (clinicaltrials.gov) - Aug 8, 2014
P1, N=28, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Initiation date: May 2001 --> Oct 2001
- || Leukine (sargramostim) / Partner Therap, lorukafusp alfa (APN301) / Apeiron Biologics
Trial primary completion date: Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - Aug 1, 2014
P2, N=52, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Initiation date: May 2001 --> Oct 2001 Trial primary completion date: Dec 2013 --> Dec 2014
- ||| Leukine (sargramostim) / Partner Therap, lorukafusp alfa (APN301) / Apeiron Biologics
Enrollment closed: Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - Jun 10, 2013
P2, N=52, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Dec 2013 --> Dec 2014 Suspended --> Active, not recruiting
- | lorukafusp alfa (APN301) / Apeiron Biologics
Enrollment change: hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma (clinicaltrials.gov) - Mar 6, 2013
P2, N=39, Completed, Sponsor: Children's Oncology Group
Suspended --> Active, not recruiting N=60 --> 39
- lorukafusp alfa (APN301) / Apeiron Biologics
Trial completion, Metastases: Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma (clinicaltrials.gov) - Oct 14, 2012
P2, N=23, Completed, Sponsor: University of Wisconsin, Madison
N=60 --> 39 Recruiting --> Completed
- lorukafusp alfa (APN301) / Apeiron Biologics
Enrollment change, Metastases: Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma (clinicaltrials.gov) - Dec 4, 2011
P2, N=23, Completed, Sponsor: University of Wisconsin, Madison
Recruiting --> Completed N=16 --> 23